A bumper crop of revisions, including a stronger drug benefit, means the plan you enrolled in for 2024 may not be the best fit next year.
Category: Drugs (Pharmaceuticals)
-
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
-
States Revive Lawsuit to Sharply Curb Access to Abortion Pill
The Supreme Court ruled in June that the original plaintiffs, anti-abortion doctors and groups, did not have standing to sue. Now three states are trying to continue the legal fight.
-
CVS Ousts Karen Lynch as C.E.O. and Shares Fall
Shares of the health care conglomerate dropped after the sudden departure of Karen Lynch and a downbeat update on the state of the company’s finances.
-
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
-
U.S. Races to Replace IV Fluid Supplies After Hurricane Helene
Officials are looking to foreign sources to ease shortages of IV bags caused by Hurricane Helene as hospitals begin rationing fluids to protect the sickest patients.
-
On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics
Both have campaigned for lower prescription costs. Kamala Harris has promised to expand President Biden’s policies. Donald Trump is a wild card.
-
How Cannabis and Opium Poppies Became National Security Issues
After supply chain disruptions that made critical medicines scarce, a federal effort is underway to ensure domestic stocks of pharmaceutical ingredients.
-
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
-
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
-
Biden Officials Stave Off Sticker Shock on Medicare Drug Premiums
Federal regulators spent billions of dollars to avoid a spike in costs for older Americans that could have been politically damaging to the presidential campaign of Vice President Kamala Harris.
-
F.D.A. Approves a New Antipsychotic Drug
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.